Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
6.71
+0.02 (0.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Acrivon Therapeutics Employees
As of December 31, 2023, Acrivon Therapeutics had 61 total employees, including 58 full-time and 3 part-time employees. The number of employees increased by 17 or 38.64% compared to the previous year.
Employees
61
Change (1Y)
17
Growth (1Y)
38.64%
Revenue / Employee
n/a
Profits / Employee
-$1,261,918
Market Cap
208.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 834 |
| SOPHiA GENETICS | 430 |
| Utah Medical Products | 190 |
| Inhibrx Biosciences | 172 |
| Profound Medical | 131 |
| Zentalis Pharmaceuticals | 124 |
| Lexeo Therapeutics | 58 |
| Inhibikase Therapeutics | 9 |
ACRV News
- 8 days ago - Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
- 2 months ago - Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewsWire
- 3 months ago - Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects - Seeking Alpha
- 3 months ago - Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis - GlobeNewsWire
- 6 months ago - Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias? - Seeking Alpha
- 7 months ago - Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire